These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15316338)

  • 21. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.
    Koval CE; Dykes C; Wang J; Demeter LM
    Virology; 2006 Sep; 353(1):184-92. PubMed ID: 16797050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*.
    Cozzi-Lepri A; Paredes ; Phillips AN; Clotet B; Kjaer J; Von Wyl V; Kronborg G; Castagna A; Bogner JR; Lundgren JD;
    HIV Med; 2012 Jan; 13(1):62-72. PubMed ID: 21848790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
    Casado JL; Hertogs K; Ruiz L; Dronda F; Van Cauwenberge A; Arnó A; Garcia-Arata I; Bloor S; Bonjoch A; Blazquez J; Clotet B; Larder B
    AIDS; 2000 Jan; 14(2):F1-7. PubMed ID: 10708276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutations associated with hypersusceptibility...and with good adherence.
    Barfod TS
    J Infect Dis; 2004 Dec; 190(11):2056-7; author reply 2057. PubMed ID: 15529273
    [No Abstract]   [Full Text] [Related]  

  • 26. Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda.
    Eshleman SH; Laeyendecker O; Parkin N; Huang W; Chappey C; Paquet AC; Serwadda D; Reynolds SJ; Kiwanuka N; Quinn TC; Gray R; Wawer M
    AIDS; 2009 Apr; 23(7):845-52. PubMed ID: 19276794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C.
    Grossman Z; Istomin V; Averbuch D; Lorber M; Risenberg K; Levi I; Chowers M; Burke M; Bar Yaacov N; Schapiro JM;
    AIDS; 2004 Apr; 18(6):909-15. PubMed ID: 15060438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients.
    Falloon J; Ait-Khaled M; Thomas DA; Brosgart CL; Eron JJ; Feinberg J; Flanigan TP; Hammer SM; Kraus PW; Murphy R; Torres R; Masur H;
    AIDS; 2002 Feb; 16(3):387-96. PubMed ID: 11834950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study.
    Matthews GV; Sabin CA; Mandalia S; Lampe F; Phillips AN; Nelson MR; Bower M; Johnson MA; Gazzard BG
    AIDS; 2002 Jan; 16(1):53-61. PubMed ID: 11741163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher virological effectiveness of NNRTI-based antiretroviral regimens containing nevirapine or efavirenz compared to a triple NRTI regimen as initial therapy in HIV-1-infected adults.
    Pérez-Elías MJ; Moreno A; Moreno S; López D; Antela A; Casado JL; Dronda F; Gutiérrez C; Quereda C; Navas E; Abraira V; Rodríguez MA
    HIV Clin Trials; 2005; 6(6):312-9. PubMed ID: 16452065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.
    Tolle M; Howard L; Kirk B; Gomila A; Schwarzwald H; Anabwani G
    J Int Assoc Physicians AIDS Care (Chic); 2012; 11(4):260-8. PubMed ID: 21972264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.
    Ochoa de Echagüen A; Arnedo M; Xercavins M; Martinez E; Rosón B; Ribera E; Domingo P; González A; Riera M; Llibre JM; Gatell JM; Dalmau D;
    AIDS; 2005 Sep; 19(13):1385-91. PubMed ID: 16103769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.
    Brenner B; Turner D; Oliveira M; Moisi D; Detorio M; Carobene M; Marlink RG; Schapiro J; Roger M; Wainberg MA
    AIDS; 2003 Jan; 17(1):F1-5. PubMed ID: 12478089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.
    Langmann P; Weissbrich B; Desch S; Väth T; Schirmer D; Zilly M; Klinker H
    Eur J Med Res; 2002 Jul; 7(7):309-14. PubMed ID: 12176680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rare mutations at codon 103 of HIV-1 reverse transcriptase can confer resistance to non-nucleoside reverse transcriptase inhibitors.
    Harrigan PR; Mo T; Wynhoven B; Hirsch J; Brumme Z; McKenna P; Pattery T; Vingerhoets J; Bacheler LT
    AIDS; 2005 Mar; 19(6):549-54. PubMed ID: 15802972
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays.
    Shulman NS; Delgado J; Bosch RJ; Winters MA; Johnston E; Shafer RW; Katzenstein DA; Merigan TC
    J Acquir Immune Defic Syndr; 2005 May; 39(1):78-81. PubMed ID: 15851917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
    Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
    HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: a randomized, double-blind, placebo-controlled trial.
    Haas DW; Fessel WJ; Delapenha RA; Kessler H; Seekins D; Kaplan M; Ruiz NM; Ploughman LM; Labriola DF; Manion DJ
    J Infect Dis; 2001 Feb; 183(3):392-400. PubMed ID: 11133370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption.
    Darwich L; Esteve A; Ruiz L; Bellido R; Clotet B; Martinez-Picado J
    Antivir Ther; 2008; 13(7):945-51. PubMed ID: 19043929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.